RASolute 303 Phase 3 Trial for Metastatic Pancreatic Cancer

So exciting for KRAS mutant PDAC patients. We are testing PP2A molecular glues in combination with these drugs in a wide variety of KRAS mutant cancers https://lnkd.in/g8DF54du

Subcutaneous injections are a newer, patient-friendly way to deliver immunotherapy for kidney cancer. They help simplify treatment while maintaining the same therapeutic benefits—making care more accessible and efficient for patients and providers alike. Learn more. https://bit.ly/40XMFNC

The journey through ovarian cancer treatment is incredibly challenging, and sometimes it brings unexpected side effects, even in your mouth. Knowing this surprising link can be key to staying more comfortable during care. Learn about common oral side effects and how to manage them effectively: https://lnkd.in/dzfaSCip

Advanced bladder cancer care is evolving rapidly, not just with new therapies but in how we test earlier for HER2, sequence treatments, and proactively manage toxicity. This expert commentary highlights real-world use of HER2-targeted ADCs and the impact on timely patient care. 👉 Read more: https://lnkd.in/gZesp_BP #OncologyCare #BladderCancer #ClinicalInsights

A new option for a challenging disease setting. With the approval of relacorilant + nab-paclitaxel, clinicians now have an additional strategy for treating platinum-resistant ovarian cancer. Key considerations: ✔️ Modest but meaningful survival benefit ✔️ Safety profile consistent with chemotherapy ✔️ Monitoring for adrenal insufficiency and steroid interactions As treatment options expand, so does the complexity of care. 🔗 Learn more: https://lnkd.in/gmxSNpcT #ClinicalOncology #CancerTreatment #Pharmacy #oncology #cancer #pharmacyleadership

A new option for a challenging disease setting. With the approval of relacorilant + nab-paclitaxel, clinicians now have an additional strategy for treating platinum-resistant ovarian cancer. Key considerations: ✔️ Modest but meaningful survival benefit ✔️ Safety profile consistent with chemotherapy ✔️ Monitoring for adrenal insufficiency and steroid interactions As treatment options expand, so does the complexity of care. 🔗 Learn more: https://lnkd.in/gmxSNpcT #ClinicalOncology #CancerTreatment #Pharmacy #oncology #cancer #pharmacyleadership

“The widely anticipated results of this study indicate that daraxonrasib provides a clear and highly meaningful step forward for patients with pancreatic cancer who have experienced progression on prior treatment, typically chemotherapy. I believe that this new approach is a very important advance for the field that I expect will be practice-changing for physicians and improve the care for patients with previously treated metastatic pancreatic cancer.” https://lnkd.in/erv_NG9X

On a recent episode of The Bio Report podcast, Immuneering Corporation CEO Ben Zeskind, PhD shared how we’re rethinking targeted cancer therapy by challenging the conventional wisdom of continuous dosing. Our approach leverages precisely timed, high-intensity pulses designed to restore natural signaling rhythms in healthy cells while repeatedly disrupting tumors—aiming to delay resistance, improve tolerability, and extend patient benefit. This is a shift from continuous suppression to biologically informed precision. Listen to “Outsmarting Resistance with Rhythm”: https://lnkd.in/dxCfF8YN #Biotech #Oncology #CancerResearch #DrugDevelopment #PrecisionMedicine

📊 Important real-world data being presented today at #AACR2026 highlight the significant unmet need facing Cyclin E1-positive ovarian cancer patients. 🔬The analysis of two independent patient cohorts consistently demonstrated that Cyclin E1-positive patients experience worse clinical outcomes with standard-of-care therapies 💡These findings reinforce the rationale for our biomarker-driven approach with our investigational WEE1 inhibitor in the DENALI and ASPENOVA registration-intended trials. 🔗 View the full poster on our website: https://lnkd.in/ec3DAGVH